multi-virus-specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01570283)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multi-virus-specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05101213 | Phase 1 | Dec 1, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT01570283 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Baylor University, Methodist Cancer Center, Houston, Texas, ViraCyte |
| NCT07104591 | N/A | — | Baylor University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
| ViraCyte | For profit | 1 | 1 | 1 | 2012 |
5 organizations
Page 1 / 1